With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first.
|Slideshows|October 19, 2018
Six Ways Psoriasis Costs Extend Well Beyond Treatment of One Condition
Author(s)Karen Appold
Individuals with immune-mediated diseases, such as psoriasis, are at higher risk for having other immune-mediated diseases. Here’s how psoriasis can lead to other conditions, and the associated costs.
Advertisement
Advertisement
Related to this article
A structured approach grounded in implementation science and supported by a culture that values continuous improvement can enable organizations to identify barriers, align stakeholders and sustain new practices over time.
New unattended sleep testing codes take effect Jan. 1, 2027 — but a dispute over how CMS values them could shape access to the cheaper alternative to in-lab sleep studies.
A session at AAO 2026 explained how Medicare, Medicare Advantage and commercial coverage policies differ in ophthalmology, and how practices can document and code to stay compliant
Presenters at AAO 2026 examined hospital eye coverage gaps, workforce strain and how ophthalmology can gain influence within health systems.
Price transparency data on 11 glaucoma surgery codes showed payer class was most consistently tied to price, with Medicaid and self-pay rates lowest.
Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.
Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Ophthalmology coverage hinges on knowing the payer | AAO 2026
2
A conversation about the cycle of ADHD and sleep problems in children, with Alison Pritchard, Ph.D.
3
Experts urge earlier JAK inhibitor use in AD and vitiligo | Fall Clinical Derm 2026
4
2026 PBMI Annual National Conference
5